Sotera Health Past Earnings Performance
Past criteria checks 2/6
Sotera Health's earnings have been declining at an average annual rate of -9.8%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 7.8% per year. Sotera Health's return on equity is 15%, and it has net margins of 6.3%.
Key information
-9.8%
Earnings growth rate
-8.4%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 7.8% |
| Return on equity | 15.0% |
| Net Margin | 6.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sotera Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,120 | 70 | 175 | 0 |
| 30 Jun 24 | 1,098 | 40 | 167 | 0 |
| 31 Mar 24 | 1,077 | 55 | 163 | 0 |
| 31 Dec 23 | 1,049 | 51 | 160 | 0 |
| 30 Sep 23 | 991 | -306 | 180 | 0 |
| 30 Jun 23 | 976 | -268 | 177 | 0 |
| 31 Mar 23 | 988 | -261 | 173 | 0 |
| 31 Dec 22 | 1,004 | -234 | 166 | 0 |
| 30 Sep 22 | 993 | 121 | 163 | 0 |
| 30 Jun 22 | 971 | 123 | 158 | 0 |
| 31 Mar 22 | 956 | 135 | 152 | 0 |
| 31 Dec 21 | 931 | 115 | 149 | 0 |
| 30 Sep 21 | 907 | 36 | 152 | 0 |
| 30 Jun 21 | 881 | 9 | 150 | 0 |
| 31 Mar 21 | 842 | -26 | 140 | 0 |
| 31 Dec 20 | 818 | -39 | 137 | 0 |
| 30 Sep 20 | 795 | -23 | 119 | 0 |
| 30 Jun 20 | 790 | -28 | 128 | 0 |
| 31 Mar 20 | 772 | -29 | 132 | 0 |
| 31 Dec 19 | 778 | -21 | 132 | 0 |
| 31 Dec 18 | 746 | -6 | 126 | 0 |
Quality Earnings: SH5 has a large one-off loss of $84.7M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: SH5 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SH5 has become profitable over the past 5 years, growing earnings by -9.8% per year.
Accelerating Growth: SH5 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: SH5 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (-0.7%).
Return on Equity
High ROE: SH5's Return on Equity (15%) is considered low.